Jane Street Group LLC Has $306,000 Position in Loxo Oncology Inc (LOXO)

Share on StockTwits

Jane Street Group LLC decreased its position in Loxo Oncology Inc (NASDAQ:LOXO) by 43.8% during the fourth quarter, HoldingsChannel reports. The firm owned 2,183 shares of the biopharmaceutical company’s stock after selling 1,701 shares during the quarter. Jane Street Group LLC’s holdings in Loxo Oncology were worth $306,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Gotham Asset Management LLC increased its position in shares of Loxo Oncology by 69.5% during the 4th quarter. Gotham Asset Management LLC now owns 4,335 shares of the biopharmaceutical company’s stock valued at $607,000 after purchasing an additional 1,777 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in Loxo Oncology by 359.7% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,611 shares of the biopharmaceutical company’s stock worth $1,206,000 after acquiring an additional 6,738 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in Loxo Oncology by 7.8% in the 4th quarter. Nuveen Asset Management LLC now owns 8,831 shares of the biopharmaceutical company’s stock worth $1,237,000 after acquiring an additional 637 shares in the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Loxo Oncology by 45.9% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 200,673 shares of the biopharmaceutical company’s stock worth $28,107,000 after acquiring an additional 63,131 shares in the last quarter. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in Loxo Oncology in the 4th quarter worth approximately $2,773,000. Institutional investors own 96.49% of the company’s stock.

LOXO stock opened at $234.66 on Tuesday. Loxo Oncology Inc has a 1-year low of $101.70 and a 1-year high of $234.93. The company has a market capitalization of $7.18 billion, a price-to-earnings ratio of -44.19 and a beta of 2.51.

Several research firms recently issued reports on LOXO. BidaskClub lowered shares of Loxo Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, February 13th. Leerink Swann lowered shares of Loxo Oncology from an “outperform” rating to a “market perform” rating in a report on Monday, January 7th. William Blair reissued a “buy” rating on shares of Loxo Oncology in a report on Monday, January 7th. Citigroup lowered shares of Loxo Oncology from a “buy” rating to a “neutral” rating in a report on Tuesday, January 8th. Finally, Ifs Securities lowered shares of Loxo Oncology from an “outperform” rating to a “market perform” rating in a report on Monday, January 7th. Eight analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $198.58.

TRADEMARK VIOLATION WARNING: “Jane Street Group LLC Has $306,000 Position in Loxo Oncology Inc (LOXO)” was reported by Zolmax and is owned by of Zolmax. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://zolmax.com/investing/jane-street-group-llc-has-306000-position-in-loxo-oncology-inc-loxo/3038659.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Recommended Story: What is the float in trading stocks?

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

The Newest: EU’s Tusk says Notre Dame fire will be Defeat
The Newest: EU’s Tusk says Notre Dame fire will be Defeat
Flushing Financial  Raised to Hold at BidaskClub
Flushing Financial Raised to Hold at BidaskClub
The Latest: Renovations firm says Safety measures followed
The Latest: Renovations firm says Safety measures followed
ValuEngine Lowers Flexsteel Industries  to Sell
ValuEngine Lowers Flexsteel Industries to Sell
Hawaiian  Raised to “Hold” at BidaskClub
Hawaiian Raised to “Hold” at BidaskClub
SunPower  Lowered to “Hold” at ValuEngine
SunPower Lowered to “Hold” at ValuEngine


 
© 2006-2019 Zolmax.